Bioscan Research’s innovative device that detects traumatic brain injury has won Unitus Seed Fund’s StartHealth competition which offers a funding of Rs 6 lakh in cash.
12th July 2017, New Delhi: Out of 186 startups who applied for Unitus Seed Fund’s StartHealth competition, Bioscan Research has been chosen for a fund of Rs 6 lakh in cash for its innovative device that can detect internal brain injury. Along with Nanosniff Technologies, which was declared as a runner up for its innovation for early detection of heart attack, Bioscan Research can now pitch for a funding of up to Rs 4 crore at Unitus Seed Fund’s AmpHealth program.
Shilpa Malik, founder, Bioscan Research, shared with ETHealthworld about the device, “We are making non-invasive handheld system with which head injured patients can be scanned for any internal bleeding. Within 2-3 minutes, the results can be seen, which further helps in transiting the patient from the place of accident to the right healthcare facility. For example, patients with internal bleeding in their head can be directly shifted to tertiary healthcare provider. India is called injury capital of the world, as road accidents are very prominent. The device can create an impact at tier II and tier III cities where people don’t have easy access to neurosurgeons. The device doesn’t require any special skill set for operating it except 20-30 minutes of training, following which any trained person would be able to use the device effectively.”
According to neuro specialists, symptoms of brain injury, called delayed haematoma, could be misleading post the road accident. “In this, timely transportation of the patient from the affected area to the right facility is extremely important. In case of delayed haematoma, the symptoms could be misleading such as some sort of headache and discomfort for which patients usually have a painkiller and go for sleep, instead of consulting a neuro specialist. In this case, brain injury detector could be a saviour via timely diagnosis and treatment,” said Malik. The target audience for the product, which may cost around Rs 1 lakh, could be general physicians, clinicians, hospitals, family doctors and paramedic staff.
Bioscan’s plan is to refine the product specifications and functionalities in 3-5 months and develop the final product in one year, followed by setting up of the assembly plant.
“We are currently testing our handheld system in hospitals. We have simulated the diseases in the lab, tried to detect it and the device has worked fine so far. Now, we are at clinical testing stage and beginning to test it on real human subjects,” said Malik.